Clinical Trial

Pulmonary Rehabilitation Program in Patients With Post-Tuberculosis Lung Disease

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Post-tuberculosis lung disease (PTLD) refers to persistent respiratory symptoms, functional limitation, and/or structural or physiological abnormalities after completion of anti-tuberculosis treatment. These consequences can reduce exercise capacity and quality of life. This randomized controlled study will evaluate whether an individualized pulmonary rehabilitation program provides greater and more sustained improvement than standard care in adults with PTLD. Participants will be allocated in a 1:1 ratio to an 8-week supervised pulmonary rehabilitation program plus standard care or to standard care alone. Assessments will be performed at baseline (T0), immediately after the 8-week program (T1), and 3 months after program completion (T2; Week 20). The primary outcome will be the change in St George's Respiratory Questionnaire total score from baseline to Week 20. Secondary outcomes will include exercise capacity, mobility, dyspnea, perceived exertion, additional quality-of-life measures, blood-cell-derived inflammatory indices, adherence, and adverse events.
Trial Details
NCT Number NCT07709507
Lead Sponsor Filantropia Hospital
Conditions Post-tuberculosis Lung Disease, Tuberculosis (TB)
Enrollment 80 participants
Start Date 2026-08-01
Primary Completion 2026-11-15 (estimated)
Study Completion 2026-12-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-16